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Abstract Exacerbations of chronic heart failure (HF)
with the necessity for hospitalisation impact hospi-
tal resources significantly. Despite all of the achieve-
ments in medical management and non-pharmaco-
logical therapy that improve the outcome in HF, new
strategies are needed to prevent HF-related hospitali-
sations by keeping stable HF patients out of the hos-
pital and focusing resources on unstable HF patients.
Remote monitoring of these patients could provide
the physicians with an additional tool to intervene
adequately and promptly. Results of telemonitoring
to date are inconsistent, especially those of telemon-
itoring with traditional non-haemodynamic parame-
ters. Recently, the CardioMEMS device (Abbott Inc.,
Atlanta, GA, USA), an implantable haemodynamic re-
mote monitoring sensor, has shown promising results
in preventing HF-related hospitalisations in chronic
HF patients hospitalised in the previous year and in
New York Heart Association functional class III in the
United States. This review provides an overview of the
available evidence on remote monitoring in chronic
HF patients and future perspectives for the efficacy
and cost-effectiveness of these strategies.
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Introduction
The management of patients with chronic heart fail-
ure (HF) places a high burden on health care resources
due to the frequent follow-up visits combined with re-
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current hospitalisations due to cardiac decompensa-
tion [1]. Early detection of HF deterioration is crucial
to prevent HF-related hospitalisations, potentially im-
prove overall survival and quality of life and lower the
burden on health care resources. Remote monitor-
ing of chronic HF patients can aid in the detection of
HF deterioration; therefore several remote monitor-
ing strategies have been developed. In this review, we
provide an overview of available evidence on remote
monitoring of chronic HF patients and provide fur-
ther perspectives of anticipated developments in the
remote care of HF.
Non-haemodynamic remote monitoring
Over the last few decades, several studies have investi-
gated the use of non-haemodynamic remote monitor-
ing. However, the results have been largely inconsis-
tent. A recently updated Cochrane review included 41
randomised controlled trials (RCTs) investigating the
use of structured telephone support (25 studies, 9332
patients) or non-invasive telemonitoring (18 studies,
3860 patients) compared with standard HF care [2].
This review showed a modest beneficial effect of re-
mote monitoring on all-cause mortality and HF-re-
lated hospitalisations, although no effect on the over-
all hospitalisation rates was observed. However, the
quality of the evidence of this review is limited by
the many different inclusion and exclusion criteria for
patients included in the studies and considerably het-
erogeneity of compared data. Also, the studies in-
cluded used different intervention therapies, ranging
from telephone calls only, weight monitoring to com-
plex multiple-variable telemonitoring strategies mak-
ing it difficult to conclude which component drives
the effect. Additionally, the majority of selected indi-
vidual studies (more than twenty) were neutral.
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Table 1 Non-invasive remote monitoring in heart failure (HF) patientsa
Trial/study Author; journal; year No. of
patients
Parameter Endpoint Impact on HF hospi-
talisation
TEN-HMS [5] Cleland et al.;
J Am Coll Cardiol; 2005
426 Signs/symptoms, daily weights,
BP, nurse telephone calls
HF hospitalisation Non-significant
TELE-HF [4] Chaudhry et al.;
N Engl J Med; 2010
1653 Signs/symptoms, daily weights HF hospitalisation Non-significant
TIM-HF [7] Koehler F et al.;
Circulation; 2011
710 Signs/symptoms, daily weights HF hospitalisation Non-significant
INH [3] Angermann et al.;
Circ Heart Fail; 2012
715 Signs, symptoms, telemonitoring
nurse coordinated
HF hospitalisation Non-significant
WISH [10] Lynga et al.;
Eur J Heart Fail; 2012
344 Daily weights HF hospitalisation Non-significant
CHAT [9] Krum et al.;
Cardiovasc Ther; 2013
405 Monthly telephone-based auto-
mated telemedicine system
HF hospitalisation Non-significant
BEAT-HF [11] Ong et al.;
JAMA Intern Med; 2016
1437 Signs, symptoms, daily weights,
nurse communications
HF hospitalisation Non-significant
TIM-HF2 [6] Koehler F et al.;
Lancet; 2018
1571 Web-based remote monitoring
on daily weight, BP, pulse, ECG,
peripheral capillary oxygen satura-
tion, a self-related health status.
ECG and BP machine at home
Reduction in the weighted
average of ‘the % of days
lost due to unplanned CV
hospital admissions or
death’
HR 0.80; 95% CI
0.65–1.00
BP blood pressure, CV cardiovascular, ECG electrocardiography
aDemonstrating the landmark trials only, sample size >250 patients, discounting studies with only phone calls as intervention
Multiple large multi-centre prospective clinical
studies and RCTs have investigated multiple non-
invasive remote monitoring strategies, ranging from
symptom and body weight monitoring to complex
and intensive strategies including body weight, blood
pressure, electrocardiography and peripheral capil-
lary oxygen saturation. The landmark studies of high
quality design and well specified intervention show
no consistent beneficial effect of non-haemodynamic
remote monitoring in HF patients (Tab. 1; [3–11]). Of
specific note and most promising are the recent re-
sults of TIM-HF2 trial showing a benefit on all-cause
mortality and cardiovascular hospitalizations of a well
structured but labour intensive 24/7 telemonitoring
strategy, but remarkably showed no effect on qual-
ity of life [6]. Also, ‘real-world’ data, such as those
from the Medicare database, did not show consistent
benefits of non-haemodynamic remote monitoring
strategies on mortality or hospitalisation rates [12].
Our conclusion is that although results are inconsis-
tent for non-invasive telemonitoring, the simplicity
makes it potentially useful for larger groups of HF
patients at relatively lower risk or less symptomatic,
where invasive telemonitoring may have more impact
in sicker patients.
Remote monitoring using pacemaker/ICD devices
Multiple studies have investigated the remote mon-
itoring abilities of implantable cardioverter defibril-
lator/cardiac resynchronisation therapy (ICD/CRT)
devices in chronic HF patients to improve HF-re-
lated hospitalisation rates (Tab. 2). The MORE-CARE
multi-centre RCT showed that remote monitoring of
advanced diagnostics via CRT-D did not reduce mor-
tality or hospitalisation rates, although the health care
resource utilisation was reduced due to a reduction
in outpatient follow-up visits [13]. Additionally, the
DOT-HF, OptiLink and REM-HF trials investigated the
use of remote monitoring using ICD/CRT devices, but
all failed to show a reduction in HF-related hospital-
isation rates [14–16]. The DOT-HF trial even showed
an increase in the number of HF hospitalisations
in the remotely monitored groups[16]. The EFFECT
study, a multi-centrer clinical trial, showed that re-
mote monitoring of ICD in HF patients reduced mor-
tality and cardiovascular hospitalisations [17], and the
COMMIT-HF trial showed that remote monitoring of
ICD/CRT HF patients significantly reduces long-term
mortality but not HF-related hospitalisations [18].
Other patient outcomes have been investigated as
well, with mixed results. The IN-TIME RCT showed
that using the remote monitoring abilities of the ICD
and CRT devices leads to a reduction of a combined
endpoint of all-cause death, overnight HF-related hos-
pitalisation, change in New York Heart Association
(NYHA) class, and change in patient global self-as-
sessment [19]. However, other trials found no signif-
icant effect on patient outcomes [20, 21]. The effect
of remote monitoring using ICD/CRT devices has re-
cently been investigated in a meta-analysis, including
11 RCTs (5702 patients). This meta-analysis showed
a reduction in the number of outpatient visits in re-
motely monitored patients, although remote monitor-
ing with an ICD/CRT device had no effect onmortality
or HF-related hospitalisations rates in these patients
[22].
The MultiSENSE algorithm aims to predict the in-
dividualised risk for worsening of HF based on first
and third heart sounds, thoracic impedance, respira-
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Table 2 Remote monitoring in heart failure (HF) patients using implantable cardioverter defibrillator/cardiac resynchronisa-
tion therapy (ICD/CRT) devices
Trial/study Author; journal; year No. of
patients
Parameter Endpoint Impact on HF hospitalisation
DOT-HF [16] Van Veldhuisen et al.;
Circulation; 2011
335 Intrathoracic impedance HF hospitalisation Increased
OptiLink [14] Brachmann et al.;
Eur J Heart Fail; 2011
1002 Intrathoracic impedance HF hospitalisation Non-significant
EFFECT [17] De Simone et al.;
Europace; 2015
987 Remote monitoring via
ICD, or CRT
HF hospitalisation Reduced
(IRR 0.54; 95% CI 0.24–0.62)
MORE-CARE [13] Boriani et al.;
Eur J Heart Fail; 2017
865 Remote monitoring of
advanced diagnostics via
CRT-D
HF hospitalisation Non-significant
REM-HF [15] Morgan et al.;
Eur Heart J; 2017
1650 Remote monitoring via
ICD, or CRT
HF hospitalisation Non-significant
COMMIT-HF [18] Kurek et al.;
J Cardiovasc Electrophysiol;
2017
574 Remote monitoring via
ICD, or CRT
HF hospitalisation/
All-cause mortality
Non-significant/
Reduced all-cause mortality
(HR 0.24; 95% CI 0.14–0.41)
IN-TIME [19] Hindricks et al;
Lancet; 2014
716 Remote monitoring via
ICD, or CRT
HF worsening score OR 0.63 95% Ci 0.43–0.90
tion rate, the ratio of respiration rate to tidal volume,
heart rate and patient activity. This could aid in the
timely detection of HF worsening with the threshold
retrospectively calculated by the algorithm. However,
the overall sensitivity is only 70% [23]. Another algo-
rithm with a similar aim is the HeartLogic algorithm
[24]. To date, no clinical endpoint data or trial data
are available and the technique is limited to certain
ICD types and brands only.
The shift in remote HF care: haemodynamic
(invasive) remote monitoring
In HF patients cardiac filling pressures rise weeks
before an exacerbation of HF leading to a related hos-
pitalisation. Symptoms of clinical congestion such as
gain in body weight will occur about 2 weeks later,
usually shortly before hospitalisation (Fig. 1; [25]).
Monitoring of cardiac filling pressures can be an
effective strategy to detect upcoming HF decompen-
sation, as it might provide a window of opportunity
Fig. 1 Pathophysiology of
decompensated heart fail-
ure. (Reprinted from [54],
with permission)
to intervene adequately and promptly, which is not
possible with previous remote monitoring strategies.
Therefore multiple implantable haemodynamic mon-
itoring devices have been developed over the last few
years. The ePAD (Medtronic, Dublin, Irland) device,
an estimate pulmonary artery (PA) end-diastolic pres-
sure device, can be implanted in the right ventricle
and has been investigated in the COMPASS-HF trial.
In this trial, NYHA class III/IV chronic HF patients
were included and investigated as to whether remote
haemodynamic monitoring using the ePAD could re-
duce HF-related hospitalisation, emergency or urgent
care visits requiring intravenous therapy. This study
did not find significant differences in its endpoint, al-
though it was underpowered due to a lower inclusion
rate. Furthermore, clinicians did not receive guidance
on how to react to pressure changes [26].
Left atrium pressures (LAP) can be directly mea-
sured using a LAP device. The tip of this device is im-
planted transvenously into the atrial septum oriented
towards the left atrium, enabling remote LAP moni-
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Fig. 2 CardioMEMS HF system, consisting of the pulmonary artery pressure sensor (a) and the patient electronics system (b)
used to take daily pressure readings. (Courtesy of Abbott, Inc.)
toring. This device was used only in the LAPTOP-HF
trial, which aimed to investigate the safety and effec-
tiveness of this sensor. However, the enrollment was
stopped early due to a perceived excess of procedure-
related complications. This is an important issue as
the procedure needs an interatrial septum puncture
and is placed in the left side of the heart with the
risk of arterial side complications. However, in the
patients already included in this trial, and followed
for 12 months, a 41% reduction of HF-related hospi-
talisations was observed in the patients with a LAP
device [27]. Currently, the V-LAP™ Left Atrium Moni-
toring systEm for Patients With Chronic sysTOlic and
Diastolic Congestive heaRt Failure (VECTOR-HF) trial
is investigating a new LAP device (V-LAP; Vectorious
Medical Technologies Ltd., Tel Aviv, Israel) to assess
the safety, performance and usability of this device in
NYHA class III HF patients (NCT03775161).
Off all the remote monitoring strategies currently
available, remote haemodynamic monitoring using
the CardioMEMS HF system device (Abbott Inc.,
Atlanta, GA, USA) (Fig. 2) appears to be the most
promising with respect to safety, durability and abil-
ity to prevent HF-related hospitalisations. The Car-
dioMEMS is implanted into the PA and enables daily
pulmonary artery pressure (PAP) readings. Treating
physicians can react to these changes in PA trend data
to maintain normal PAP levels, as a sign of a stable
clinical status. Furthermore, these daily PAP readings
can be used as a feedback mechanism after treat-
ment changes, providing feedback on whether the
treatment changes led to a sufficient decline of PAPs.
These strategies can lead to individualised HF therapy.
The CardioMEMS consists of a coil combined with
a pressure-sensitive capacitor sealed in a capsule,
forming an electrical circuit that resonates at a spe-
cific frequency when it is electromagnetically coupled
with an external antenna [28]. This antenna provides
the power for the device, so the device is completely
free from batteries or leads. At both sides of the cap-
sule, a loop is placed to ensure that the CardioMEMS
remains at the implanted position until the endothe-
lialisation is complete, approximately 3–4 weeks after
implantation. When pressure is applied, the resonant
frequency changes via a characteristic pattern and is
received by the external antenna. The antenna con-
verts this signal into a pressure waveform and sends
it to a secure website, where it can be monitored. The
device is implanted during a right heart catheterisa-
tion, with access via the femoral vein. An appropriate
target location, based on vessel size and location,
is identified on a pulmonary arteriogram. The Car-
dioMEMS delivery system is advanced to the target
location over a guidewire, where the CardioMEMS is
released. After implantation, the device is calibrated
using PAP obtained with a Swan Ganz catheter.
Two studies have validated the PAP measured by
the CardioMEMS, with cardiac filling pressures mea-
sured by Swan-Ganz catheterisation or echocardiogra-
phy directly after implantation and after 6 months of
follow-up [29, 30]. Swan-Ganz measurements showed
a good correlation with mean PAP assessed by Car-
dioMEMS (r2= 0.90at implantation and r2= 0.94at fol-
low-up, p< 0.01) [30]. Furthermore, a good correlation
(r2= 0.80at implantation and r2= 0.75, both p< 0.01at
follow-up) was found between PAP measurements by
the CardioMEMS and estimated pressure measure-
ments by echocardiography [29].
Safety
The safety of the CardioMEMS has been investi-
gated in the CHAMPION trial. A total of 15 serious
adverse events occurred during all implantation at-
tempts in the CHAMPION trial [31]. In total, 1%
(n= 8) of patients developed a device-related adverse
event, and 1% (n=7) developed a procedure-related
adverse event. The following events were reported:
four bleeding events, three anticoagulation-related
hospitalisations, two pre-existing atrial dysrhythmia
exacerbations during implantation, two febrile ill-
nesses, one pulmonary in situ thrombus during im-
plantation that was treated with anticoagulation, one
cardiogenic shock, one case of atypical chest pain,
and one delivery-system failure requiring a snare to
remove the delivery system [32]. An analysis of the
post-marketing data of more than 5500 CardioMEMS
implantations showed that 2.8% of all CardioMEMS
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Fig. 3 Cumulative heart-failure-related hospitalisations during the entire period of randomised single-blind follow-up (a), and
freedom fromfirst heart-failure-relatedhospitalisation ormortality (b) in the CHAMPION trial. (Reprinted from [32], with permission)
patients experienced an adverse event [33]. Most
adverse events were a recalibration of the system
(n= 35) or access-site-related bleeding (n= 15). The
reported adverse event rates are comparable with
those of a standard right heart catheterisation, which
is considered a safe procedure [34]. The recent US
Post Approval Study (PAS) reported a device- or sys-
tem-related complication in 0.3% of all patients, and
a sensor failure in only 0.1% of all patients, which
confirms the safety and durability of this technique.
Clinical efficacy
The CardioMEMS was investigated for the first time
in the CHAMPION trial [32]. In this trial, 550 patients
with NYHA class III HF and at least one hospitali-
sation in the last year received a CardioMEMS and
were randomised. Of the patients in the intervention
group, the haemodynamic information was available
to the treating physicians, and the physicians were in-
structed to react on pressure changes. In the control
group, the CardioMEMS readings were not available
to the physicians, and these patients received only
the standard care. Using the haemodynamic feed-
back in the intervention group led to a significantly
higher number of medication changes, especially di-
uretics and vasodilator changes, compared to the con-
trol group [35]. Furthermore, remote monitoring with
the CardioMEMS device led to a significant reduction
in mean PAP [32, 36]; similar results were observed in
a real-world setting [37].
The effectiveness of the CardioMEMS in prevent-
ing HF-related hospitalisations has been investigated
in multiple studies ([32, 36, 38, 39]; Fig. 3). Dur-
ing the first 6 months of remote monitoring of HF
patients, the HF hospitalisation rates declined by ap-
proximately 30% [32, 38] compared with standard
care. During the long-term follow-up, the sustained
reduction was approximately 33% [31, 38, 39]. Also,
all-cause hospitalisation rates were reduced: 45% at
6 months [38] and 16% at 18 months of follow-up
[31]. None of these studies were powered to observe
mortality differences; however, the CHAMPION trial
showed a strong trend towards survival benefit in
HF and reduced ejection fraction (HFrEF) patients
monitored with the CardioMEMS system (p= 0.06)
[40].
The recently presented PAS results confirm the con-
sistent treatment benefit with CardioMEMS in chronic
HF patients, reducing the number of HF hospitalisa-
tions in a more contemporary setting. The PAS study
showed a 58% reduction in HF-related hospitalisation
in the first year after CardioMEMS implantation com-
pared with 1 year before implantation. Furthermore,
a reduction in HF hospitalisations, mortality and all-
cause mortality was observed after CardioMEMS im-
plantation. However, patients included in the PAS
study were their own historical controls and there
has been no randomised comparison to standard care
without PA monitoring.
CardioMEMS and evidence in HFpEF patients
In a real-world setting, remote monitoring using the
CardioMEMS leads to a similar reduction in mean
PAP in both HFrEF and HFpEF patients [37]. Inter-
estingly, in the CHAMPION trial, a larger reduction of
HF-related hospitalisations in HFpEF patients com-
pared with HFrEF patients was observed after at least
6 months of remote monitoring [40, 41]. Besides the
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Fig. 4 Differences between the United States and the
Netherlands in the use of (a) and dosing of (b) guideline-
recommended medication in patients with heart failure and
reduced ejection fraction in the CHAMP-HF [43] and CHECK-
HF [44] registries. MRA mineralocorticoid receptor antagonist
(Adapted from [43, 44], with permission)
alleged benefit of spironolactone in the United States
(US) and European participants of the TOPCAT trial
[42] with spironolactone, this is the first evidence of
a treatment or tool to improve the outcome in HFpEF
patients.
Standard care in chronic HF
Recently two large HF registries have been published,
the CHAMP-HF registry [43] from the USA and the
CHECK-HF Registry [44] from The Netherlands. These
two registries showed the differences in standard care
between the USA and Western Europe. The prescrip-
tion rates of RAS inhibitors (82.3% vs 59.9%), beta
blockers (80.6% vs 66.8%) and mineralocorticoid re-
ceptor antagonist (MRA) (54.8% vs 33.1%) in HFrEF
patients were much higher in the CHECK-HF registry
compared to the CHAMP-HF registry (Fig. 4a). Fur-
thermore, the prescribed dosages differed between
the two registries, with higher prescribed dosages for
RAS inhibitors in the CHECK-HF registry and higher
dosages for MRA in the CHAMP-HF registry (Fig. 4b)
Differences in the HF readmission rates were observed
between the USA and Europe [45, 46]. The generalis-
ability of the US findings in terms of clinical effective-
ness when using the CardioMEMS device in addition
to standard care is therefore limited, and additional
costs cannot be directly extrapolated between the two
different health care structures. Additional research is
needed in the European setting. In Germany, the Car-
dioMEMS European Monitoring Study for Heart Fail-
ure (MEMS-HF) study was set up as a post-marketing
study to test the safety and clinical effectiveness in
a European setting but lacks a control group [47].
Cost-effectiveness of CardioMEMS
The cost-effectiveness of remote monitoring using
the CardioMEMS is highly relevant. Using the US
CHAMPION trial data the incremental cost-effective
ratio (ICER, cost per quality-adjusted life-year) for
the US setting has been calculated [32, 48–50]. These
studies estimated an increase in the quality-adjusted
life-years in the CardioMEMS group of between 0.28
and 0.58, with incremental costs between $4282 and
$20,079, compared with standard care patients. This
results in an estimated ICER in the USA of between
$13,379 and $71,462, which are additional costs in or-
der to gain one quality-adjusted life-year in patients
monitored with the CardioMEMS device. Sensitivity
analyses demonstrated that the cost-effectiveness of
the CardioMEMS is highly influenced by device costs,
costs of routine outpatient care, hospitalisation rates,
mortality rates and duration of remote monitoring
using the CardioMEMS.
There are no patient-level data for cost-effective-
ness analyses in Western Europe. With assumptions
and estimations based on extrapolating data from the
CHAMPION trial and despite the large differences in
standard care and financial systems, Cowie et al. [51]
calculated the ICER in the European setting, which
was approximately between 22,555 (for the Nether-
lands) and 23,814 (for Germany). However, all these
analyses used data on the reduction of HF hospital-
isation from the CHAMPION trial and used different
estimated mortality rates from population-based co-
horts for the cost-effectiveness analyses.
Health care utilisation
Two studies investigated the potential reduction of
health care utilisation achieved by using the Car-
dioMEMS [38, 52]. In a real-world Medicare database,
1-year remote monitoring with the CardioMEMS led
to an $11,260 cost reduction for HF hospitalisations
compared with 1 year before the CardioMEMS im-
plantation [38]. Based on the effects reported in the
CHAMPION trial, and the expected prevalence and
hospitalisation costs in Germany, remote monitoring
with the CardioMEMS could lead to an overall cost
reduction of 106,000,000 in Germany in 2021 [52].
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As shown above, remote monitoring of PAP with the
CardioMEMS in chronic HF patients leads to more
medication changes and a larger reduction of PAP
compared with patients receiving standard care, indi-
cating that these patients receive more individualised
HF care. In the US, this strategy was effective in reduc-
ing the number of HF-related and all-cause hospital-
isations. It was suggested that this strategy could im-
prove mortality rates and has been shown to be cost-
effective. However, as discussed earlier, some impor-
tant differences in HF care exist between the USA and
Europe.
Recommendation of ESC 2016 guidelines on
remote monitoring
The 2016 ESC guidelines report on the lack of consis-
tent evidence for non-haemodynamic telemonitoring
or remote monitoring in HF patients. The guidelines
state that remote monitoring may be considered in
selected patients to improve HF outcome with indi-
vidual approaches such as CardioMEMS to reduce the
risk of HF admissions and multi-parameter monitor-
ing with ICD (in-time approach) to improve outcome
in HFrEF patients with a level IIb class B recommen-
dation [53].
Conclusion
In recent years, many remote monitoring strategies
have been developed, and development continues
at a rapid rate. Non-invasive remote monitoring
of symptoms and signs, as well as weight, has not
been proven to be effective in improving outcome
measurements. Also, the monitoring of biomarkers
or thoracic impedance has not been shown to be
beneficial. Invasive or haemodynamic measures of
remote monitoring are developed with right-sided
(CardioMEMS) and left-sided (LA devices) sensors.
The LAPTOP-HF trial with LA devices was stopped
early for safety reasons. The CardioMEMS is the most
promising (invasive) remote monitoring tool currently
available. The haemodynamic information allows for
a window of timely and adequate intervention based
upon raised PAP, preventing an upcoming HF decom-
pensation. Additionally, its safety and durability have
been tested and confirmed in post-marketing studies.
However, important information on the effect on the
quality of life and cost-effectiveness is still lacking in
a Western European setting, which is currently being
investigated in the MONITOR-HF study.
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